We apply our proprietary AP3 patient selection platform to develop targeted precision oncology medicines that we match to patients whose tumors are predicted to be sensitive to each specific medicine. Our clinical pipeline is initially focused on an advanced asset targeting the DNA Damage Response (DDR) and cell cycle regulation with demonstrated, durable single agent clinical activity in solid tumors but where genetics-based approaches have proven insufficient for response prediction. Likewise, our preclinical programs target critical nodes in DDR pathways where we believe genetics-based approaches are insufficient for patient responder prediction. Our OncoSignature® patient selection method will be used to aim for patient responder enrichment to increase the likelihood of successful clinical development.
Acrivon’s Lead Program ACR-368 (also known as Prexasertib, in-licensed from Lilly), is a clinically-advanced, potent selective inhibitor of the DNA Damage Response checkpoint kinases, CHK1 and CHK2. ACR-368 has demonstrated deep, durable single-agent anti-tumor clinical activity, including complete responses, in a proportion of patients with platinum-resistant ovarian cancer* and squamous cell cancer ‡. Using OncoSignature®, we have identified endometrial and bladder cancer as two additional high unmet need solid tumor types predicted to be highly sensitive to the drug candidate. Our two preclinical lead series target critical nodes in the DNA Damage Response and cell cycle pathways.
*Ref: Lee et al, Lancet Oncology (2018); ‡ Ref: Hong et al, CCR (2018)